Working… Menu

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03636685
Recruitment Status : Unknown
Verified August 2018 by Shi Yuankai, Chinese Academy of Medical Sciences.
Recruitment status was:  Not yet recruiting
First Posted : August 17, 2018
Last Update Posted : August 17, 2018
Information provided by (Responsible Party):
Shi Yuankai, Chinese Academy of Medical Sciences